We are live on ! Find out more
PRAX icon

Praxis Precision Medicines
PRAX

74 hedge funds and large institutions have $196M invested in Praxis Precision Medicines in 2023 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more capital invested

Capital invested by funds: $135M → $196M (+$61M)

5% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 20

0.26% more ownership

Funds ownership: 5.68% → 5.93% (+0.26%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

5% less funds holding

Funds holding: 78 → 74 (-4)

21% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 14

Holders
74
Holders Change
-4
Holders Change %
-5.13%
% of All Funds
1.17%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
11
Increased
21
Reduced
20
Closed
14
Calls
$145K
Puts
–
Net Calls
+$145K
Net Calls Change
+$94K

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$4.04M
2
IC
Ikarian Capital
Texas
+$2.84M
3
BlackRock
BlackRock
New York
+$1.6M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.08M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.07M

Top Sellers

1
SFM
Sphera Funds Management
Israel
-$4.94M
2
ABG
Ally Bridge Group
New York
-$2.7M
3
Verition Fund Management
Verition Fund Management
Connecticut
-$1.8M
4
MS
Maven Securities
Jersey
-$1.55M
5
Millennium Management
Millennium Management
New York
-$1.34M
Name Holding Trade Value Shares
Change 		Change in
Stake
Point72 Asset Management
1
Point72 Asset Management
Connecticut
$17.8M -$210K -11,081 -2%
CAM
2
Cormorant Asset Management
Massachusetts
$16.2M – – –
Verition Fund Management
3
Verition Fund Management
Connecticut
$15.5M -$1.8M -95,200 -14%
PHS
4
PFM Health Sciences
California
$15.3M +$35.6K +1,882 +0.3%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$15M +$1.07M +56,624 +11%
Vanguard Group
6
Vanguard Group
Pennsylvania
$9.51M +$4.04M +213,303 +135%
VA
7
VR Adviser
New York
$9.07M – – –
KCM
8
Kingdon Capital Management
New York
$8.89M – – –
VCIM
9
Velan Capital Investment Management
Georgia
$8.87M – – –
TLP
10
Tri Locum Partners
New York
$8.3M -$36.4K -1,922 -0.6%
SFM
11
Sphera Funds Management
Israel
$8.29M -$4.94M -260,935 -45%
ACP
12
Acuta Capital Partners
California
$7.67M +$296K +15,667 +6%
Bank of America
13
Bank of America
North Carolina
$7.13M -$355K -18,738 -6%
SCM
14
Silverarc Capital Management
Massachusetts
$7.04M +$809K +42,784 +18%
IC
15
Ikarian Capital
Texas
$3.85M +$2.84M +150,000 New
BBA
16
Baker Bros. Advisors
New York
$3.21M – – –
BlackRock
17
BlackRock
New York
$3.21M +$1.6M +84,728 +210%
CIBC Asset Management
18
CIBC Asset Management
Ontario, Canada
$3.12M +$373K +19,695 +19%
VVA
19
Vida Ventures Advisors
Massachusetts
$2.51M – – –
Acadian Asset Management
20
Acadian Asset Management
Massachusetts
$2.45M -$137K -7,249 -7%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$2.22M +$1.08M +56,993 +193%
SCM
22
Soleus Capital Management
Connecticut
$1.97M -$1.2M -63,333 -45%
ABG
23
Ally Bridge Group
New York
$1.81M -$2.7M -142,908 -67%
Blackstone Inc
24
Blackstone Inc
New York
$1.8M – – –
7IH
25
72 Investment Holdings
Connecticut
$1.69M – – –
1
2 3 4

PRAX Hedge Fund Activity: Q3 2023 in Review

74 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q3 2023, worth a combined $196M — up 45% from $135M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of PRAX and 11 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 21 added.

The largest buyer was Vanguard Group, adding an estimated $4.04M. The largest seller was Sphera Funds Management, cutting an estimated $4.94M.

  • 74 institutional investors held Praxis Precision Medicines (PRAX) as of Q3 2023, down from 78 in Q2 2023.
  • Funds reported $196M of Praxis Precision Medicines stock for Q3 2023, up 45% quarter-over-quarter.
  • 11 funds opened new Praxis Precision Medicines positions in Q3 2023 and 14 closed out, a net change of -3 holders.
  • The largest Praxis Precision Medicines buyer in Q3 2023 was Vanguard Group, an estimated $4.04M added.
  • The largest Praxis Precision Medicines seller in Q3 2023 was Sphera Funds Management, an estimated $4.94M sold.

Based on aggregated 13F filings for Q3 2023.